| TL;DR Mounjaro is a weekly injection for weight loss and type 2 diabetes, helping reduce appetite and control blood sugar. It’s prescription-only but can be accessed via private consultations without a GP. Eligibility depends on BMI and health conditions; it is not suitable for everyone. Compared to Wegovy, it may deliver greater weight loss, but the choice varies by patient. |
Mounjaro has become one of the most talked-about weight loss treatments in the UK and for good reason. Clinical trials have shown it produces greater weight loss than any previously approved obesity medication, with some participants losing over 20% of their body weight. Demand has surged, NHS waiting lists are long, and thousands of people across the UK are now turning to their local pharmacy to access it privately.
At Cleckheaton Pharmacy, we help patients navigate these questions every week. This guide answers all of them, clearly, honestly, and without confusion.
What Is Mounjaro, and How Does It Work?
Mounjaro is the brand name for tirzepatide, a weekly injectable medication originally developed for type 2 diabetes management. It was approved by the MHRA in the UK for chronic weight management in adults with obesity in November 2023, under the brand name Mounjaro (a separate approval from its diabetes use).
Tirzepatide works differently from earlier weight loss injections like semaglutide (Wegovy/Ozempic). It is a dual agonist — meaning it activates two hormone receptors simultaneously:
- GLP-1 (glucagon-like peptide-1): Slows gastric emptying, reduces appetite, and improves blood sugar regulation
- GIP (glucose-dependent insulinotropic polypeptide): Enhances insulin secretion, reduces fat storage, and may further suppress appetite through a separate pathway
By activating both pathways, tirzepatide produces a stronger and more sustained effect on appetite, food intake, and metabolic function than drugs targeting GLP-1 alone.
What Do the Clinical Trials Actually Show?
The evidence for Mounjaro’s effectiveness is genuinely impressive. The SURMOUNT clinical trial programme tested tirzepatide in thousands of adults with obesity and produced results that reshaped the landscape of obesity treatment:
- At the highest dose (15mg weekly), participants lost an average of 22.5% of their body weight over 72 weeks
- At 10mg weekly, average weight loss was 21.4%
- At 5mg weekly, average weight loss was 16%
- The majority of participants on the highest dose lost more than 20% of body weight
For context, earlier GLP-1 medications like liraglutide (Saxenda) produced average weight losses of around 5–7%. Semaglutide (Wegovy) produced average losses of around 15%. Tirzepatide represents a step-change in what pharmacological treatment can achieve.
These results come with the consistent caveat that they occur in the context of a reduced-calorie diet and increased physical activity.
Can I Get Mounjaro at a Pharmacy Without a GP?
You cannot simply walk in and buy Mounjaro over the counter. It is a prescription-only medication (POM) and requires a valid prescription from an authorised prescriber. However, that prescriber does not have to be a GP.
At Cleckheaton Pharmacy, we work with a structured private prescription pathway that allows eligible patients to access Mounjaro without waiting for an NHS referral or GP appointment. Here is how it works:
Step 1 — Online or in-person consultation
A brief clinical assessment covering your weight, BMI, medical history, and current medications is completed by an independent prescriber. This can be done online through an approved provider or in person at our pharmacy.
Step 2 — Prescription issued
If you meet the eligibility criteria, a prescription for Mounjaro is issued. This is a private prescription.
Step 3 — Dispensed at Pharmacy
We dispense your Mounjaro, provide full injection training, and answer any questions about starting treatment.
Step 4 — Ongoing support
We provide follow-up support, monitor your progress, and can help you titrate your dose according to the prescriber’s plan.
Who is Eligible for Mounjaro?
The MHRA-approved criteria for Mounjaro (tirzepatide) in the UK for weight management are:
- BMI of 30 kg/m² or above (obesity), OR
- BMI of 27 kg/m² or above (overweight) with at least one weight-related health condition such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease
Mounjaro is not suitable for:
- Women who are pregnant or breastfeeding
- People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- People with a history of pancreatitis
- Those with severe gastrointestinal disease
- Children and adolescents under 18
A full clinical assessment is required before any prescription is issued. At Cleckheaton Pharmacy, we conduct thorough consultations and will not prescribe to patients who do not meet clinical criteria.
What Are the Side Effects?
The most common side effects of Mounjaro are gastrointestinal and typically occur in the early weeks of treatment as your body adjusts:
- Nausea (most common, particularly at dose initiation)
- Vomiting
- Diarrhoea or constipation
- Reduced appetite (this is partly the mechanism of action)
- Injection site reactions (redness, bruising, mild discomfort)
These side effects are usually mild to moderate and resolve over time. The gradual dose titration schedule starts at 2.5mg and increases every four weeks to minimise gastrointestinal discomfort.
More serious but rare adverse effects include pancreatitis, gallbladder problems, and an increased heart rate. Your prescriber will discuss these risks during your consultation.
Important: If you experience severe abdominal pain that radiates to your back, persistent vomiting, or signs of an allergic reaction, seek medical attention immediately.
Mounjaro vs Wegovy: Which Is Better?
This is a question we are asked regularly. Both are injectable weight loss medications. Both work on GLP-1 receptors. But there are meaningful differences:
Wegovy (semaglutide) targets GLP-1 only and produces an average weight loss of around 15% at the highest dose. Mounjaro (tirzepatide) targets both GLP-1 and GIP, producing average weight loss of around 20–22% at its highest dose. Head-to-head trial data (SURMOUNT-5) published in 2024 confirmed that tirzepatide produced significantly greater weight loss than semaglutide in direct comparison.
However, individual responses vary. Some patients respond better to semaglutide. Tolerability, medical history, and cost all factor into the decision. Our team at Cleckheaton can discuss both options with you and help you understand which is most appropriate for your situation.
Why Choose Cleckheaton Pharmacy?
Accessing weight loss medication online through unregulated channels is a genuine safety risk. Counterfeit GLP-1 products have been identified in the UK market. At Cleckheaton Pharmacy, you receive:
- Medication dispensed from a GPhC-registered, regulated premises
- Full injection training and technique support
- Ongoing pharmacist-led monitoring
- Transparent pricing with no pressure
- A clinical team that will tell you honestly if this treatment is not right for you
FAQs
What is Mounjaro used for?
Mounjaro is used to treat type 2 diabetes and support weight loss. It helps control blood sugar and reduces appetite by targeting hormones involved in insulin and hunger regulation.
What is the main purpose of tirzepatide?
Tirzepatide improves blood sugar control and promotes weight loss by mimicking hormones that regulate insulin secretion, appetite, and digestion.
Who cannot take tirzepatide?
People with a history of medullary thyroid cancer, MEN2 syndrome, severe gastrointestinal disease, or hypersensitivity should avoid it. Always consult a doctor before starting treatment.